Analyst Downgrades – Esperion Therapeutics (NASDAQ:ESPR) Stock Gets Downgraded By Citigroup from Buy to Neutral

0

Analyst Ratings For Esperion Therapeutics (NASDAQ:ESPR)

Today, Esperion Therapeutics (NASDAQ:ESPR) stock was downgraded by Citigroup from Buy to Neutral with a price target of $96.00.

Some recent analyst ratings include

  • 1/22/2018-Citigroup was Downgraded by analysts at Citigroup from a “Buy ” rating to a ” Neutral” rating. They now have a $96.00 price target on the stock, up previously from $77.00 .
  • 1/17/2018-Credit Suisse Group initiated coverage with a Outperform rating.
  • 1/5/2018-Bank of America Upgrade from a “Neutral ” rating to a ” Buy” rating.
  • 12/14/2017-Needham & Company LLC Upgrade from a “Buy ” rating to a ” Strong-Buy” rating.
  • 11/10/2017-Northland Securities Reiterated Rating of Buy.

Recent Insider Trading Activity For Esperion Therapeutics (NASDAQ:ESPR)
Esperion Therapeutics (NASDAQ:ESPR) has insider ownership of 32.50% and institutional ownership of 92.30%.

  • On 12/6/2017 Nicole Vitullo, Director, sold 9,326 with an average share price of $53.85 per share and the total transaction amounting to $502,205.10.
  • On 3/22/2017 Dov A Md Goldstein, Director, sold 800,000 with an average share price of $41.66 per share and the total transaction amounting to $33,328,000.00.
  • On 3/21/2017 Gilbert S Omenn, Director, bought 1,000 with an average share price of $42.26 per share and the total transaction amounting to $42,260.00.
  • On 11/1/2016 Narendra D Lalwani, COO, bought 5,000 with an average share price of $9.93 per share and the total transaction amounting to $49,650.00.
  • On 7/6/2016 Mark E Mcgovern, Director, bought 5,000 with an average share price of $10.00 per share and the total transaction amounting to $50,000.00.
  • On 5/4/2016 Timothy M Mayleben, CEO, bought 7,000 with an average share price of $14.85 per share and the total transaction amounting to $103,950.00.
  • On 3/1/2016 Gilbert S Omenn, Director, bought 5,000 with an average share price of $15.28 per share and the total transaction amounting to $76,400.00.

Recent Trading Activity for Esperion Therapeutics (NASDAQ:ESPR)
Shares of Esperion Therapeutics closed the previous trading session at 77.23 up +0.03 0.04% with 85006 shares trading hands.